Orange County Entrepreneur Banks On Data-Based Approach To Detect, Treat Diseases
IV BioHoldings CEO Marty Keiser connects data, technology, capital and people to create start-ups focusing on liquid biopsy programs.
You may also be interested in...
Foundation Medicine and Novartis’ commercial partnership has achieved another success as Foudation’s Liquid CDx is approved.
Guardant Health Launches New Firsts: Blood Test To Track Patient’s Response To Immunotherapy, Tissue-Based Test
Guardant’s launch of a new test to track patient’s response to immunotherapy or targeted drugs and new pan-cancer tissue test, brings it closer to “one-stop-shop” in cancer care continuum.
Deal-making and financing activities are on the rise for liquid biopsy diagnostic products in 2021 despite questions remaining around whether the technology can unseat standard-of-care biomarker and imaging tests.